ATROPINE
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $313,986 | 40 | 0 |
| 2023 | $704,001 | 72 | 1 |
| 2022 | $240,374 | 49 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 161 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multicenter, Double-Masked, Randomized, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Atropine 0.1% and 0.01% Ophthalmic Solutions Administered With a Microdose Dispenser for the Reduction of Pediatric Myopia Progression | Bausch & Lomb Americas Inc. | $1.3M | 1 |
Top Doctors Receiving Payments for ATROPINE
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Birmingham, AL | $1.3M | 160 |
| , OD | Optometrist | Glendale, AZ | $3,802 | 1 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.3M
- Total Doctors 1
- Transactions 161
About ATROPINE
ATROPINE is a drug associated with $1.3M in payments to 1 healthcare providers, recorded across 161 transactions in the CMS Open Payments database. The primary manufacturer is Bausch & Lomb Americas Inc..
Payment data is available from 2022 to 2024. In 2024, $313,986 was paid across 40 transactions to 0 doctors.
The most common payment nature for ATROPINE is "Unspecified" ($1.3M, 100.0% of total).
ATROPINE is associated with 1 research study, including "A Multicenter, Double-Masked, Randomized, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Atropine 0.1% and 0.01% Ophthalmic Solutions Administered With a Microdose Dispenser for the Reduction of Pediatric Myopia Progression" ($1.3M).